StonvexLoading…
StonvexStonvexStonvexCore line items from IVFH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $60.68M | $59.45M | $70.39M | $78.90M |
Operating Income | $2.64M | $1.27M | $-2.81M | $-805.71K |
Net Income | $-2.07M | $2.61M | $-4.36M | $-1.35M |
EPS (Diluted) | $0.05 | $0.08 | $-0.08 | $-0.02 |
Total Assets | $19.58M | $27.35M | $21.32M | $23.42M |
Total Liabilities | $13.34M | $19.17M | $18.52M | $16.83M |
Cash & Equivalents | $927.47K | $1.28M | $5.24M | $4.78M |
Free Cash Flow OCF − CapEx | $-269.68K | $-6.59M | $-557.97K | $-714.05K |
Shares Outstanding | 54.65M | 53.16M | 49.71M | 46.59M |